These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 25547867)

  • 1. Are capecitabine and the active metabolite 5-Fu CNS penetrable to treat breast cancer brain metastasis?
    Zhang J; Zhang L; Yan Y; Li S; Xie L; Zhong W; Lv J; Zhang X; Bai Y; Cheng Z
    Drug Metab Dispos; 2015 Mar; 43(3):411-7. PubMed ID: 25547867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study.
    Bachelot T; Romieu G; Campone M; Diéras V; Cropet C; Dalenc F; Jimenez M; Le Rhun E; Pierga JY; Gonçalves A; Leheurteur M; Domont J; Gutierrez M; Curé H; Ferrero JM; Labbe-Devilliers C
    Lancet Oncol; 2013 Jan; 14(1):64-71. PubMed ID: 23122784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcomes in patients who received lapatinib plus capecitabine combination therapy for HER2-positive breast cancer with brain metastasis and a comparison of survival with those who received trastuzumab-based therapy: a study by the Anatolian Society of Medical Oncology.
    Kaplan MA; Isikdogan A; Koca D; Kucukoner M; Gumusay O; Yildiz R; Dayan A; Demir L; Geredeli C; Kocer M; Arslan UY; Inal A; Akman T; Coskun U; Sener N; Inanc M; Elkiran ET; Ozdemir NY; Durnalı AG; Suner A; Alici S; Tarhan MO; Boruban C; Oksuzoglu B; Urakci Z
    Breast Cancer; 2014 Nov; 21(6):677-83. PubMed ID: 23335064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer.
    Lin NU; Diéras V; Paul D; Lossignol D; Christodoulou C; Stemmler HJ; Roché H; Liu MC; Greil R; Ciruelos E; Loibl S; Gori S; Wardley A; Yardley D; Brufsky A; Blum JL; Rubin SD; Dharan B; Steplewski K; Zembryki D; Oliva C; Roychowdhury D; Paoletti P; Winer EP
    Clin Cancer Res; 2009 Feb; 15(4):1452-9. PubMed ID: 19228746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Positive interaction between lapatinib and capecitabine in human breast cancer models: study of molecular determinants.
    Chefrour M; Milano G; Formento P; Giacometti S; Denden A; Renée N; Iliadis A; Fischel JL; Ciccolini J
    Fundam Clin Pharmacol; 2012 Aug; 26(4):530-7. PubMed ID: 21623901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases.
    Lin NU; Eierman W; Greil R; Campone M; Kaufman B; Steplewski K; Lane SR; Zembryki D; Rubin SD; Winer EP
    J Neurooncol; 2011 Dec; 105(3):613-20. PubMed ID: 21706359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study.
    Morikawa A; Peereboom DM; Thorsheim HR; Samala R; Balyan R; Murphy CG; Lockman PR; Simmons A; Weil RJ; Tabar V; Steeg PS; Smith QR; Seidman AD
    Neuro Oncol; 2015 Feb; 17(2):289-95. PubMed ID: 25015089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. All-oral combination of lapatinib and capecitabine in patients with brain metastases from HER2-positive breast cancer--a phase II study.
    Shawky H; Tawfik H
    J Egypt Natl Canc Inst; 2014 Dec; 26(4):187-94. PubMed ID: 25294797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complete response of brain metastases from breast cancer overexpressing Her-2/neu to radiation and concurrent Lapatinib and Capecitabine.
    Abboud M; Saghir NS; Salame J; Geara FB
    Breast J; 2010; 16(6):644-6. PubMed ID: 21070441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High serum TGF-α predicts poor response to lapatinib and capecitabine in HER2-positive breast cancer.
    Rhee J; Han SW; Cha Y; Ham HS; Kim HP; Oh DY; Im SA; Park JW; Ro J; Lee KS; Park IH; Im YH; Bang YJ; Kim TY
    Breast Cancer Res Treat; 2011 Jan; 125(1):107-14. PubMed ID: 20936340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lapatinib for the treatment of HER2-overexpressing breast cancer.
    Jones J; Takeda A; Picot J; von Keyserlingk C; Clegg A
    Health Technol Assess; 2009 Oct; 13 Suppl 3():1-6. PubMed ID: 19846022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of HER2-positive metastatic breast cancer with lapatinib and capecitabine in the lapatinib expanded access programme, including efficacy in brain metastases--the UK experience.
    Sutherland S; Ashley S; Miles D; Chan S; Wardley A; Davidson N; Bhatti R; Shehata M; Nouras H; Camburn T; Johnston SR
    Br J Cancer; 2010 Mar; 102(6):995-1002. PubMed ID: 20179708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer.
    Gajria D; Gonzalez J; Feigin K; Patil S; Chen C; Theodoulou M; Drullinsky P; D'Andrea G; Lake D; Norton L; Hudis CA; Traina TA
    Breast Cancer Res Treat; 2012 Jan; 131(1):111-6. PubMed ID: 21898114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer.
    Martin M; Bonneterre J; Geyer CE; Ito Y; Ro J; Lang I; Kim SB; Germa C; Vermette J; Wang K; Wang K; Awada A
    Eur J Cancer; 2013 Dec; 49(18):3763-72. PubMed ID: 23953056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcomes of HER2-positive metastatic breast cancer patients with brain metastasis treated with lapatinib and capecitabine: an open-label expanded access study in Korea.
    Ro J; Park S; Kim S; Kim TY; Im YH; Rha SY; Chung JS; Moon H; Santillana S
    BMC Cancer; 2012 Jul; 12():322. PubMed ID: 22839200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.
    Pivot X; Manikhas A; Żurawski B; Chmielowska E; Karaszewska B; Allerton R; Chan S; Fabi A; Bidoli P; Gori S; Ciruelos E; Dank M; Hornyak L; Margolin S; Nusch A; Parikh R; Nagi F; DeSilvio M; Santillana S; Swaby RF; Semiglazov V
    J Clin Oncol; 2015 May; 33(14):1564-73. PubMed ID: 25605838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lapatinib plus capecitabine resolved human epidermal growth factor receptor 2-positive brain metastases.
    Glück S; Castrellon A
    Am J Ther; 2009; 16(6):585-90. PubMed ID: 19287304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine.
    Metro G; Foglietta J; Russillo M; Stocchi L; Vidiri A; Giannarelli D; Crinò L; Papaldo P; Mottolese M; Cognetti F; Fabi A; Gori S
    Ann Oncol; 2011 Mar; 22(3):625-630. PubMed ID: 20724575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses.
    Cameron D; Casey M; Press M; Lindquist D; Pienkowski T; Romieu CG; Chan S; Jagiello-Gruszfeld A; Kaufman B; Crown J; Chan A; Campone M; Viens P; Davidson N; Gorbounova V; Raats JI; Skarlos D; Newstat B; Roychowdhury D; Paoletti P; Oliva C; Rubin S; Stein S; Geyer CE
    Breast Cancer Res Treat; 2008 Dec; 112(3):533-43. PubMed ID: 18188694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating tumor cells and brain metastasis outcome in patients with HER2-positive breast cancer: the LANDSCAPE trial.
    Pierga JY; Bidard FC; Cropet C; Tresca P; Dalenc F; Romieu G; Campone M; Mahier Aït-Oukhatar C; Le Rhun E; Gonçalves A; Leheurteur M; Dômont J; Gutierrez M; Curé H; Ferrero JM; Labbe-Devilliers C; Bachelot T
    Ann Oncol; 2013 Dec; 24(12):2999-3004. PubMed ID: 24013510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.